Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $56
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $38 to $56.
Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $38 to $56.